WNK2 and melanoma: Thanks to the improved understanding of the features and drivers of melanoma, therapeutic agents targeting the mitogen-activated protein kinase pathway (e.g., BRAF inhibitors, MEK inhibitors) have been approved for patients with BRAF-mutated melanoma [4].